Prelude Therapeutics Incorporated (PRLD)
| Market Cap | 355.33M +193.4% |
| Revenue (ttm) | 22.42M +220.3% |
| Net Income | -60.49M |
| EPS | -0.72 |
| Shares Out | 102.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,091 |
| Open | 3.530 |
| Previous Close | 3.520 |
| Day's Range | 3.270 - 3.530 |
| 52-Week Range | 1.295 - 6.830 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 9.20 (+166.67%) |
| Est. Earnings | Nov 27, 2026 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel... [Read more]
Financial Performance
In 2025, Prelude Therapeutics's revenue was $12.14 million, an increase of 73.43% compared to the previous year's $7.00 million. Losses were -$99.50 million, -21.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PRLD stock is "Strong Buy." The 12-month stock price target is $9.2, which is an increase of 166.67% from the latest price.
News
Prelude Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
The portfolio centers on JAK2 JH2, a selective KAT6A degrader, and mCALR, with JAK2 in clinic and KAT6 enrollment expected soon. Initial KAT6 proof-of-concept data are planned for H2 2027; Incyte option exercise could bring $100M in non-dilutive financing.
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will parti...
H.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly
H.C. Wainwright reiterates a Buy rating on Prelude Therapeutics (PRLD) with an $8 price target after the company announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY).
Prelude enters clinical trial collaboration, supply agreement with Eli Lilly
Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY) for supply of its CDK4/6 kinase inhibitor, abemaciclib and its oral estrogen receptor ant...
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026
Prelude Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Joyce Zhou initiated coverage of Prelude Therapeutics (PRLD) with an Overweight rating and $12 price target The firm is positive on the company’s lead asset PRT12396, a JAK2V617F…
Prelude Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Multiple precision oncology programs are advancing, including a JAK2 V617F inhibitor with a major partnership and a KAT6A selective degrader entering clinical trials. Key milestones and early data readouts are expected through 2027, with innovative approaches in antibody conjugates targeting broader patient populations.
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will part...
Prelude Therapeutics receives FDA clearance for PRT13722 IND application
Prelude Therapeutics (PRLD) announced that the FDA cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT13722, an oral KAT6A selective degrader…
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cl...
Prelude Therapeutics Earnings release: Q2 2026
Prelude Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Prelude Therapeutics Quarterly report: Q2 2026
Prelude Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)
“The first six months of 2026 were highlighted by steady and strong execution across our organization,” stated Kris Vaddi, Chief Executive Officer of Prelude. “We’ve made considerable progress advanci...
Prelude Therapeutics Slides: Corporate presentation
Prelude Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline
Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontinued further development of INCB160058…
Prelude Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted a focus on differentiated cancer therapies, with KAT6A selective degraders showing strong preclinical efficacy and safety. Clinical proof-of-concept is targeted for 2027, and pipeline advances include DAC technology and a JAK inhibitor partnership with Incyte.
Prelude Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of three directors, ratification of the auditor, and approval of executive compensation and its annual review. All proposals passed by the required majority, with final results to be filed with the SEC.
Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company presented a robust precision oncology pipeline, including a selective JAK2 V617F inhibitor in phase I, a KAT6A degrader for ER+ breast cancer, and a CALR-targeted antibody-degrader conjugate. Each program is designed for improved efficacy and safety, with multiple data catalysts expected in the next 12–24 months.
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics (PRLD) with an Early-Stage Biotech rating. The firm says the company’s “differentiated approach” in metastatic breast c...
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
“Through this first quarter of 2026, our company has continued to demonstrate focused execution of the strategic priorities we set forth late last year.” stated Kris Vaddi, Chief Executive Officer…
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)
Prelude Therapeutics Earnings release: Q1 2026
Prelude Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Prelude Therapeutics Quarterly report: Q1 2026
Prelude Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Prelude Therapeutics Slides: Corporate presentation
Prelude Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Prelude Therapeutics initiated with a Buy at D. Boral Capital
D. Boral Capital initiated coverage of Prelude Therapeutics (PRLD) with a Buy rating and $9 price target Prelude is a clinical-stage oncology company advancing a precision medicine approach through a…